Document is current

Article History

Received: 29 May 2025

Accepted: 16 September 2025

First Online: 17 October 2025

Declarations

:

: John R. Ingram: Received a stipend as Editor‑in‑Chief of the British Journal of Dermatology and an authorship honorarium from UpToDate; consultant for AbbVie, Boehringer Ingelheim, ChemoCentryx, Citryll, Incyte, MoonLake Immunotherapeutics, Novartis, UCB and Union Therapeutics; has served on advisory boards for Insmed, Kymera Therapeutics and Viela Bio; co‑copyright holder of HiSQOL © and HS-IGA; his department receives income from copyright of the Dermatology Life Quality Instrument (DLQI) and related instruments. Hideki Fujita: Received honoraria or fees for serving on advisory boards, as a speaker and as a consultant, as well as grants as an investigator from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Eli Lilly, Janssen, Japan Blood Products Organization, JMEC, Kaken Pharmaceutical, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe, Nihon Pharmaceutical, Novartis, Otsuka Pharmaceutical, Sanofi, Sato Pharmaceutical, Sun Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, UCB and Ushio. Alice B. Gottlieb: Received research/educational grants from Bristol-Myers Squibb, Janssen, MoonLake Immunotherapeutics and UCB (all paid to Mount Sinai School of Medicine until May 1, 2025). Sub I at UT Southwestern on studies from Bristol-Myers Squibb, Janssen, and UCB. Received honoraria/speaker fees as an advisory board member and consultant for Bristol Myers Squibb, Eli Lilly and Company, Janssen, Novartis, Oruka, Sanofi, SunPharma, Takeda, Teva and UCB. Hadar Lev-Tov: Consultant for Novartis and UCB. Errol Prens: Consultant, advisory board member, speaker for, and received honoraria from Almirall, Janssen-Cilag, GSK, MoonLake Immunotherapeutics, Novartis, and UCB. Department has received investigator-initiated grant support from AbbVie, Celgene, CHDR, Citryll, Janssen-Cilag, Kymera, and UCB. Christopher J. Sayed: Investigator for AbbVie, AstraZeneca, ChemoCentryx, Incyte, InflaRx, Novartis and UCB; consultancy fees from AbbVie, Alumis, AstraZeneca, InflaRx, Incyte, Logical Images, MoonLake Immunnotherapeutics, Sandoz, Sanofi, Sonoma Biotherapeutics and UCB; speaker for AbbVie and Novartis. Vivian Y. Shi: On the board of directors for the Hidradenitis Suppurativa Foundation (HSF), advisor for the National Eczema Association, stock shareholder of Learn Health and has served as an advisory board member, investigator, speaker, and/or received research funding from AbbVie, Altus Lab/cQuell, Alumis, Aristea Therapeutics, Boehringer Ingelheim, Burt’s Bees, Dermira, Eli Lilly and Company, Galderma, Genentech, GpSkin, Incyte, Kiniksa, LEO Pharma, Menlo Therapeutics, MYOR, Novartis, Pfizer, Polyfins Technology, Regeneron, Sanofi Genzyme, Skin Actives Scientific, Sun Pharma, Target-PharmaSolutions and UCB. Jacek C. Szepietowski: Consultant and advisory board member of AbbVie, LEO Pharma, Novartis, Pierre Fabre, Sanofi Genzyme, Trevi Therapeutics; speaker for AbbVie, Almirall, Eli Lilly, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Sanofi-Genzyme, and UCB; investigator for AbbVie, Amgen, Bristol Myers Squibb, Galapagos, Galderma, Incyte, InflaRX, Janssen, Kiniksa, Kymab Limited, Menlo Therapeutics, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Trevi Therapeutics, and UCB. Kenzo Takahashi: Received honoraria or fees for a speaker from AbbVie, Amgen, Janssen, Kaken Pharmaceutical, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe, Sun Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, UCB and Ushio, and fees as a consultant from AbbVie, Earth Corporation, Kaken Pharmaceutical, Mitsubishi Tanabe, and UCB. Department participated in trials for AbbVie, Boehringer Ingelheim, Eli Lilly, Janssen, Kaken Pharmaceutical, Kyowa Kirin Corporation, Novartis, Sanofi, and UCB. John W. Frew: Conducted advisory work for AbbVie, Boehringer Ingelheim, ChemoCentryx, Janssen, Kyowa Kirin, LEO Pharma, Pfizer, Regeneron and UCB; participated in trials for Boehringer Ingelheim, CSL, Eli Lilly and Company, Pfizer, and UCB; received research support from Ortho Dermatologics and Sun Pharma. Jérémy Lambert, Leah Davis, Tae Oh, Robert Rolleri, Marie-Hélène Saintmard: Employees and shareholders of UCB. Lauren A.V. Orenstein: On the board of directors for the Hidradenitis Suppurativa Foundation (HSF); consultant and/or advisory board member for ChemoCentryx, Novartis, and UCB; received grant funding from Pfizer.

: The study protocol, amendments, and patient informed consent were reviewed by a national, regional, or Independent Ethics Committee (IEC) or Institutional Review Board (IRB). This study was conducted in accordance with the current version of the applicable regulatory and International Conference on Harmonisation (ICH)-Good Clinical Practice (GCP) requirements, the ethical principles that have their origin in the principles of the Declaration of Helsinki, and the local laws of the countries involved. Ethics approval was obtained from the relevant institutional review boards at participating sites. All patients provided written informed consent in accordance with local requirements.

: All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study.